The approval last year of two new products – Alkermes plc’s Lybalvi and Intra-Cellular Therapies, Inc.’s Caplyta – plus an impending US regulatory decision for BioXcel Therapeutics, Inc.’s novel treatment for agitation are shaking up a staid bipolar disorder market. More novel therapies are also in development or approaching the market for various symptoms of the mental illness, despite the many challenges to R&D in the field.
Bipolar disorder is characterized by fluctuating mood states such as mania and depression, interspersed with periods of wellbeing. After the...
